S&P 500
6,021.15
+0.3%
+$15.27
DJI
42,786.15
+0.1%
+$24.39
NASDAQ
19,642.08
+0.3%
+$50.84
Bitcoin
108,886.00
+0.4%
+390.32
AAPL
$201.87
+0.2%
+$0.42
AMZN
$216.07
-0.4%
-$0.91
GOOG
$180.34
+1.5%
+$2.71
META
$700.34
+0.9%
+$6.28
MSFT
$468.67
-0.9%
-$4.08
NVDA
$142.97
+0.2%
+$0.34
TSLA
$322.08
+4.4%
+$13.50
Clene (NASDAQ: CLNN)
$4.35
(3.1%)
$0.13
Price as of June 10, 2025, 10:49 a.m. ET
Clene Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Clene Company Info
Clene, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development of therapeutics for neurodegenerative diseases. It offers a nanotechnology drug platform for the development of a new class of orally administered neurotherapeutic drugs. The company was founded on August 12, 2020 and is headquartered in Salt Lake City, UT.
News & Analysis
Featured Article
Why Shares of Clene Jumped 11.8% on Monday
The company's lead therapy has shown progress against ALS in preliminary trials.
Jim Halley | Jul 18, 2022
Featured Article
Why Clene Stock Skyrocketed Today
One Wall Street analyst has high hopes for the biopharmaceutical company.
Prosper Junior Bakiny | Feb 3, 2021
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.